Premium
The effect of 1‐hydroxyvitamin D 3 for prolongation of leukemic transformation‐free survival in myelodysplastic syndromes
Author(s) -
Motomura Shigeki,
Kanamori Heiwa,
Ohkubo Takao,
Maruta Atsuo,
Kodama Fumio
Publication year - 1991
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830380112
Subject(s) - medicine , myelodysplastic syndromes , leukemia , gastroenterology , overall survival , hematology , oncology , bone marrow
Leukemic transformation (LT) free survival was studied in 30 patients with myelodysplastic syndromes (MDS). In 15 cases, 4–6 μg/day of 1‐hydroxyvitamin D 3 was administered, for a median duration of 17 months (D‐group), other subjects had no therapy (N group). LT free survival of the D group had significant advantage over that of the N group according to the Kaplan—Meier method ( P < 0.001). In addition, 7 cases in the N group developed acute leukemia, in contrast to only one in the D group ( P < 0.05). These results suggest that oral administration of 1‐hydroxyvitamin D 3 prevents the progression of MDS to overt leukemia under the effect of differentiation capacity from blasts to monocytes.